I’m scratching my head here.
ZB, the world's leader in total joint implant sales, just dropped $177M (before earnouts) to snag Monogram and its fancy AI-navigated robot for total knee replacements.
Monogram's mBos is a shiny toy—FDA-cleared, CT-based, semi-autonomous, with dreams of going full robot overlord by 2027.
ZB's Rosa robot is already limping behind Stryker’s Mako in the robot race. This acquisition feels like a desperate swing to patch up a shaky robotics game. It's not going to help ZB, but I understand the intent.
Since there is no internal R&D at ZB any longer, any rationale leader would leverage some of the $22B in assets at ZB, to buy stuff like P28, OrthoGrid and Monogram to try to increase sales more than their typical 4% annually while Stryker in growing revenue at 11% annually.
If I were a shareholder at ZB, I would say, "Sure, go buy stuff and try it out (but with very low expectations). Gotta do something with $20B and there is no internal R&D."
But, at the end of the day, this Monogram acquisiton is not going to help ZB sell more implants. Monogram is not the answer to ZB's revenue stagnation.
Tiger's Take: ZB's Acquisition of Monogram
Zimm...
